Vijaya R. Bhatt
Expertise in
23
conditions

Dr. Vijaya R. Bhatt

Hematology | Oncology
Fred & Pamela Buffett Cancer Center - Bellevue Health Center
2510 Bellevue Medical Center Drive, Suite 250, 
Bellevue, NE 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Expertise in
23
conditions
Fred & Pamela Buffett Cancer Center - Bellevue Health Center
2510 Bellevue Medical Center Drive, Suite 250, 
Bellevue, NE 

Overview

Vijaya Bhatt is a Hematologist and an Oncologist practicing medicine in Bellevue, Nebraska. He has been practicing medicine for over 17 years.

Dr. Bhatt is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 265 peer reviewed articles and participating in 9 clinical trials. Dr. Bhatt is currently accepting new patients.

Graduate Year

2009

Specialties

Hematology
Oncology

Fellowships

UNMC College of Medicine, Hematology/Oncology - 2015

Hospital Affiliations

Bryan Medical Center
Faith Health
Bellevue Medical Center
The Nebraska Medical Center

Languages Spoken

English
American Sign Language

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

Fred & Pamela Buffett Cancer Center - Bellevue Health Center
2510 Bellevue Medical Center Drive, Suite 250, Bellevue, NE 68123
Other Locations
Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
505 S 45th St., Omaha, NE 68105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Other, Drug
Study Drugs: Cytarabine, Decitabine, Idarubicin, Liposomal Daunorubicin, Liposomal Cytarabine, Azacitidine, Venetoclax, Glasdegib
Study Phase: Phase 2
Phase Ib Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Phase Ib Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Gemtuzumab Ozogamicin, Venetoclax
Study Phase: Phase 1
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
Ixazomib for Treatment of Chronic Graft vs. Host Disease
Ixazomib for Treatment of Chronic Graft vs. Host Disease
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

265 Total Publications

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Expertise in
34
conditions
Dr. Julie M. Vose
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (8.3 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Vose is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vose is currently accepting new patients.

Expertise in
102
conditions
Dr. Peter T. Silberstein
Hematology | Oncology
Expertise in
102
conditions
Dr. Peter T. Silberstein
Hematology | Oncology
Referral may be required
Before you request

CHI Health Henry Lynch Cancer Center At Bergan Mercy - Oncology/Hematology

7500 Mercy Rd, 
Omaha, NE 
 (8.3 miles away)
402-717-0950
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Silberstein is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Silberstein is highly rated in 102 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Hodgkin Lymphoma, Clear Cell Sarcoma, Thyroidectomy, and Prostatectomy. Dr. Silberstein is board certified in Medical Oncology - American Board Of Internal Medicine, Internal Medicine - American Board Of Internal Medicine, and Hematology - American Board Of Internal Medicine. Dr. Silberstein is currently accepting new patients.

Expertise in
20
conditions
Dr. James O. Armitage
Hematology | Oncology
Expertise in
20
conditions
Dr. James O. Armitage
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Village Pointe Health Center

111 N. 175th St., 
Omaha, NE 
 (15.0 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

James Armitage is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. Dr. Armitage is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy. Dr. Armitage is currently accepting new patients.

Frequently Asked Questions about Dr. Vijaya R. Bhatt

How do I make an appointment with Dr. Vijaya R. Bhatt?

You can book an appointment with Dr. Vijaya R. Bhatt by calling their office at 402-559-5600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vijaya R. Bhatt a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vijaya R. Bhatt is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vijaya R. Bhatt specialize in?

While Dr. Vijaya R. Bhatt is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Vijaya R. Bhatt participate in research or clinical trials?

Yes. Dr. Vijaya R. Bhatt has published 265 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Vijaya R. Bhatt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vijaya R. Bhatt accept my insurance?

Dr. Vijaya R. Bhatt accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 402-559-5600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhatt's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 12 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile